A Phase 3 interventional study of Solriamfetol and Placebo in Binge-Eating Disorder, sponsored by Axsome Therapeutics, Inc.. Enrolling by invitation at 34 sites in United States. Open to participants aged 18 Years to 56 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Axsome Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Binge-Eating Disorder with a site in United States — 20 open to participants now, 28 under way, 2 of them phase 3. Binge-Eating Disorder · United States.
Among the 122 studies in Binge-Eating Disorder with a site in United States, this one is the 16th largest by planned enrollment of the 112 interventional ones that give a count, is one of 10 that started in 2025, is one of 15 in phase 3, reaches primary completion later than 17 of the 27 other live ones, and was the 112th registered.
233 studies on the registry are indexed under Binge-Eating Disorder; 52 are open to participants now.
Browse Binge-Eating Disorder studies →20 of the 122 studies in Binge-Eating Disorder with a site in United States are open now. Recruiting first, the newest first:
Lindner Center of HOPE · Sites in United States
Ages up to 18
Trustees of Dartmouth College · Sites in United States
Ages 18–70
University of Kansas · Sites in United States
Ages 18–65
University of Oklahoma · Sites in United States
Ages 18–120
Milton S. Hershey Medical Center · Sites in United States
Ages 12–26
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 34 Binge-Eating Disorder studies recruiting now, 8 (24%) set no upper age limit and 23 (68%) stop at 75 or younger; 10 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 56 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 27 · Phase 3 25 · Phase 4 3
First in 1994; this study’s year is marked. 10 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 236 is above the median of 77 across 190 interventional studies indexed under Binge-Eating Disorder.
Median enrollment 67 across the 112 interventional studies, 224 across the 8 observational. Of the 89 that completed or were terminated, 34 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 122 have an industry lead sponsor. The 10 most frequent:
Axsome Therapeutics, Inc. is the lead sponsor of 37 studies on the registry; 12 are open to participants now.
Of its 21 completed or terminated interventional studies of FDA-regulated products, 12 (57%) have results posted.
Axsome Therapeutics, Inc. has 2 studies filed under Binge-Eating Disorder — fewer than ten, so there is no comparison to draw.
12 of the studies in Binge-Eating Disorder with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06413433Phase 3Axsome Therapeutics, Inc.Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol | 2026-12 |
| NCT06858774Icahn School of Medicine at Mount SinaiUse of Circadian Reset Technology to Alter REM Sleep and Appetitive Control in Patients With Binge Eating Disorder | 2026-11 |
| NCT06485687Ali RezaiLow Intensity Focused Ultrasound for Binge Eating Disorder | 2026-12-31 |
| NCT05664516Massachusetts General HospitalA Study of the Effects of Oxytocin in Adults With Binge-eating Disorder | 2027-01 |
| NCT03393039University of California, San DiegoEffects of Negative Affect in Individuals With Binge Eating Episodes | 2027-01 |
Add all 12 to your calendar (.ics) → With an account.
Among the 122 studies in Binge-Eating Disorder with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 3, multi-center, open-label and randomized withdrawal study to evaluate the long-term safety and efficacy of solriamfetol in the treatment of binge eating disorder (BED) in adults.
This study includes three segments: Open-Label (OL), Double-Blind Randomized Withdrawal (RW), and Open-Label Return (OLR). Eligible subjects will have completed the SOL-BED-301 (ENGAGE) study. All subjects will receive open-label solriamfetol for up to 52 weeks during the OL segment. Subjects who enter the RW segment will be randomized 1:1 to either continue solriamfetol or switch to placebo for up to 24 weeks of double-blind treatment, followed by a return to open-label solriamfetol in the OLR segment. The overall duration of study treatment is up to 77 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Experimental: Solriamfetol * Up to 52 weeks in the combined open-label and open-label return segments; * Up to 24 weeks in the double-blind randomized withdrawal segment
Drug: Solriamfetol
Up to 24 weeks in the double-blind randomized withdrawal segment
Drug: Placebo
Solriamfetol tablets, taken once daily
Placebo tablets, taken once daily
Time from randomization to relapse of binge eating in the RW segment
Time frame: Up to 24 weeks
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Dec 2027, 34 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Solriamfetol